Showing results (391-400 of 547) with videos related to

Sort By:
Pageof 55
Elife|September 20, 2022
Distance estimation from monocular cues in an ethological visuomotor taskPhilip R L Parker, Elliott T T Abe, Natalie T Beatie, et al.
Blood Advances|September 8, 2023
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphomaSamuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, et al.
ACS Synthetic Biology|April 3, 2018
Genetic Engineering of Bee Gut Microbiome Bacteria with a Toolkit for Modular Assembly of Broad-Host-Range PlasmidsSean P Leonard, Jiri Perutka, J Elijah Powell, et al.
The Journal of Allergy and Clinical Immunology|February 8, 2005
TH1-mediated airway hyperresponsiveness independent of neutrophilic inflammationJunqing Cui, Stephen Pazdziorko, Joy S Miyashiro, et al.
Blood|November 5, 1997
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma productionJ P Leonard, M L Sherman, G L Fisher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)P Martin, S-H Jung, B Pitcher, et al.
British Journal of Haematology|May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaAndres Forero-Torres, John P Leonard, Anas Younes, et al.
Leukemia & Lymphoma|February 28, 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvementJodi V Mones, Morton Coleman, Lale Kostakoglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
The radioisotope contributes significantly to the activity of radioimmunotherapyThomas A Davis, Mark S Kaminski, John P Leonard, et al.
The Lancet. Haematology|October 11, 2021
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 studySarah C Rutherford, Jeremy S Abramson, Nancy L Bartlett, et al.
Pageof 55